BioCryst Pharmaceuticals achieved full-year profitability for the first time in company history in 2025, with ORLADEYO net revenue reaching $601.8 million (+38% y-o-y). The company received FDA approval for ORLADEYO oral pellets for children ages 2-11 and completed the acquisition of Astria Therapeutics to expand its HAE portfolio with navenibart. BioCryst maintained 2026 ORLADEYO revenue guidance of $625-645 million and reported record operating profit despite selling its European ORLADEYO business.

BioCryst Pharmaceuticals announced it will present nine abstracts on its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia. The presentations include six abstracts on ORLADEYO (berotralstat), an oral prophylactic therapy for HAE patients aged 2 and older, and three on navenibart, an investigational monoclonal antibody plasma kallikrein inhibitor. A late-breaking presentation will highlight positive interim results from the ALPHA-SOLAR trial showing sustained HAE attack suppression with navenibart administered every 3 or 6 months.

BioCryst Pharmaceuticals completed its $700 million acquisition of Astria Therapeutics, adding navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development for hereditary angioedema (HAE). The acquisition strengthens BioCryst's HAE portfolio alongside its leading oral therapy ORLADEYO, with navenibart potentially offering every-three and every-six month dosing options. BioCryst financed the deal with cash on hand and $396.6 million from a Blackstone financing facility, plus 37.3 million shares issued to Astria shareholders.

Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.

BioCryst will present four abstracts at the ACAAI Annual Scientific Meeting, focusing on pediatric hereditary angioedema (HAE) research, including long-term prophylaxis data for ORLADEYO in children aged 2 to <12 years and psychosocial impact studies.

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.

BioCryst Pharmaceuticals granted stock options and restricted stock units to eight newly-hired employees, covering 115,000 shares and 91,450 shares respectively, as part of their employment inducement strategy.

BioCryst Pharmaceuticals sold its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential additional $14 million in milestones, focusing on simplifying operations and improving operating margin.

BioCryst Pharmaceuticals granted nine newly-hired employees stock options to purchase 36,700 shares and restricted stock units covering 71,400 shares of company stock, with options priced at $8.29 per share and vesting in four equal annual installments.

The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.

BioCryst Pharmaceuticals plans to present at the Cantor Global Healthcare Conference in New York on September 4, 2025, offering a live audio webcast of their presentation.

BioCryst Pharmaceuticals announced that Dr. Helen Thackray, Chief Research and Development Officer, will leave the company on September 1, 2025, transitioning to an advisory role through year-end after contributing significantly to the company's rare disease research programs.